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ABSTRACT  
Little is known about the role of flavin-containing monooxygenases (FMOs) in the 
metabolism of xenobiotics. FMO3 is the isoform in adult human liver with the highest 
impact on drug metabolism. The aim of the presented study was to elucidate the 
contribution of human FMO3 to the N-oxygenation of selected therapeutic drugs and 
drugs of abuse (DOAs). Its contribution to the in vivo hepatic net clearance of the N-
oxygenation products was calculated by application of an extended relative activity 
factor (RAF) approach to differentiate from contribution of cytochrome P450 (CYP) 
isoforms. FMO3 and CYP substrates were identified using pooled human liver 
microsomes after heat inactivation and chemical inhibition, or single enzyme 
incubations. Kinetic parameters were subsequently determined using recombinant 
human enzymes and mass spectrometric analysis via authentic reference standards 
or simple peak areas of the products divided by those of the internal standard. FMO3 
was identified as enzyme mainly responsible for the formation of N,N-
diallyltryptamine N-oxide and methamphetamine hydroxylamine (> 80% contribution 
for both). A contribution of 50 and 30% was calculated for the formation of N,N-
dimethyltryptamine N-oxide and methoxypiperamide N-oxide, respectively. However, 
FMO3 contributed with less than 5% to the formation of 3-bromomethcathinone 
hydroxylamine, amitriptyline N-oxide, and clozapine N-oxide. There was no 
significant difference in the contributions when using calibrations with reference 
metabolite standards or peak area ratio calculations. The successful application of a 
modified RAF approach including FMO3 proved the importance of FMO3 in the N-
oxygenation of DOAs in human metabolism.  
 
Keywords FMO3, CYPs, Drugs of abuse, Relative activity factor approach, Hepatic 
clearance 
1. Introduction 
Monooxygenases are responsible for the major part of the human phase I 
metabolism and convert xenobiotics to more hydrophilic compounds usually leading 
to inactivation (Cashman, 2005; Zollner et al., 2010). These monooxygenases can be 
grouped into different enzyme families such as the cytochrome P450 
monooxygenases (CYPs) and the flavin-containing monooxygenases (FMOs) (Torres 
Pazmino et al., 2010). CYPs catalyze oxygenation mainly of carbon but also of 
nitrogen and sulfur. FMOs usually oxygenate soft nucleophiles, in particular nitrogen, 
sulfur, phosphorous, and selenium atoms. Both microsomal systems have in 
common, that they transform a wide range of heteroatom-containing substrates 
(Cashman, 2005; Cruciani et al., 2014).  
In comparison to the extensively studied CYPs, FMOs have long been neglected in 
metabolism investigations. In addition, experimental conditions were usually chosen 
to optimize CYP activity rather than the activity of other oxidative enzymes leading to 
underestimation of non-CYP reactions (Strolin et al., 2006). Recently, Fan et al. 
asked for further investigations that dissect the relative contribution of FMOs 
compared to CYPs (Fan et al., 2016). Hence, only limited information about 
interactions of FMO with therapeutic drugs and drugs of abuse (DOAs) in particular is 
available. Only the oxygenation of amphetamine and methamphetamine by human 
FMO was described so far, leading to reactive metabolites (Cashman et al., 1999; 
Szoko et al., 2004). Cashman et al. reported that amphetamine and 
methamphetamine were N-oxygenated by FMO3, the major FMO isoform in the adult 
human liver. The formed hydroxylamines were also identified as FMO3 substrates 
leading to N,N-dihydroxylation followed by conversion to phenylpropanone oxime and 
phenylpropanone, respectively. Particularly the first step may pose a significant 
toxicological threat due to the potential toxic nature of free hydroxylamine (Cashman 
et al., 1999). 
Therefore, the aim of the presented study was to elucidate the contribution of FMO3 
to the human, hepatic metabolism of 12 selected, structurally different therapeutic 
drugs and eight DOAs. Its contribution to the in vivo hepatic net clearance of the N-
oxygenation products should be calculated by application of an extended relative 
activity factor (RAF) approach (Crespi and Miller, 1999; Venkatakrishnan et al., 2001) 
to differentiate from contribution of CYP isoforms. Finally, possible differences in the 
contributions should be assessed by using calibrations with reference metabolite 
standards or peak area ratio (PAR) calculations. 
 
 
2. Materials and methods 
2.1. Chemicals and enzymes 
Dimethyltryptamine (DMT) was obtained from THC Pharm (Frankfurt, Germany), 
methadone from Lipomed (Weil am Rhein, Germany), trimipramine-d3 and 
norclozapine-d8 from Promochem (Wesel, Germany), R,S-methamphetamine, 1-
aminobenzotriazole (ABT), isocitrate (IC), isocitrate dehydrogenase (IDH), 
superoxide dismutase (SOD), potassium dihydrogenphosphate (KH2PO4), and 
dipotassium hydrogenphosphate (K2HPO4) from Sigma-Aldrich (Taufkirchen, 
Germany). All other used drugs (of abuse) were supplied by commercial suppliers 
(e.g. Fluka, Neu Ulm, Germany; LG Chemicals, Teddington, UK; Lipomed, Weil am 
Rhein, Germany; Promochem, Wesel, Germany) or by the manufacturers of the 
marketed drugs. NADP+ was from Biomol (Hamburg, Germany), formic acid (MS 
grade) from Fluka (Neu-Ulm, Germany), acetonitrile, methanol (both LC MS grade), 
and all other chemicals from VWR (Darmstadt, Germany). Methanolic stock solutions 
(1 mg/mL) of the studied compounds were used. The chemical structures of all tested 
DOAs are depicted in Fig. 1. 
The baculovirus-infected insect cell microsomes (Supersomes) containing human 
complementary DNA-expressed FMO3 (5 mg protein/mL), CYP1A2, CYP2A6, 
CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4 (1 nmol/mL), or 
CYP2E1, CYP3A5 (2 nmol/mL), and pooled human liver microsomes (pHLM, 20 mg 
microsomal protein/mL, 330 pmol total CYP/mg protein) were obtained from Corning 
(Amsterdam, The Netherlands). After delivery, the microsomes were thawed at 37°C, 
aliquoted, snap-frozen in liquid nitrogen, and stored at -80°C until use. 
 
2.2. pHLM incubations  
Incubations were performed at 37°C for 30 min with 25 µM of the substrate, 
regenerating system, and 1 mg protein/mL pHLM according to (Michely et al., 2015). 
Incubations with pHLM were done without pretreatment, after preincubation with the 
chemical inhibitors ABT (2 mM) for CYPs or methimazole (200 µM) for FMOs, or after 
preheating. Heat-treated pHLM were prepared by heating at 55°C for 1 min in 
absence of NADP+ in accordance to Ring et al. (Ring et al., 1999) or at 45°C for 5 
min in absence of NADP+ and cooling on ice for 15 min in accordance to Taniguchi-
Takizawa et al. (Taniguchi-Takizawa et al., 2015). In addition, blank incubations with 
buffer instead of enzymes were performed. As described before (Michely et al., 
2015), besides enzymes and substrate, the incubation mixtures (final volume 50 L) 
contained 90 mM phosphate buffer (pH 7.4), 5 mM Mg2+, 5 mM IC, 1.2 mM NADP+, 
0.5 U/mL IDH, and 200 U/mL SOD. Reactions were initiated by addition of the 
b a e a d ed i h 50 L f ice-cold acetonitrile, co ai i g 5 M i e al 
standard. Trimipramine-d3 was used as internal standard for incubations with all 
analytes, except for amitriptyline, where norclozapine-d8 was used. The solution was 
centrifuged for 5 min at 14,000×g, 70 L f he e a a  ha e as transferred to 
a  a a le  ial a d 10 L i jec ed  he li id ch a g a h  (LC)-ion trap 
(IT)-mass spectrometry (MS) system described below. The amounts of formed 
metabolites in untreated and pretreated incubations were compared by calculating 
the PAR of the metabolites and the internal standard. All incubations were performed 
in duplicate (n = 2). 
 
2.3. Monooxygenases Activity Screening 
Incubation mixtures contained 25 µM of the test substrate and FMO3 (0.25 mg 
protein/mL), CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, 
CYP2E1, CYP3A4, CYP3A5 (50 pmol/mL, each), or pHLM (1 mg protein/mL). For 
incubations with CYP2A6 or CYP2C9, phosphate buffer was replaced with 45 or 90 
mM Tris buffer, respectively, according to the Gentest manual. Incubations were 
conducted as described in 2.2. 
 
2.4. Kinetic studies 
The kinetic constants of N-oxygenation reactions were derived from incubations with 
FMO3, single CYPs, or pHLM. Incubation time and enzyme concentration were 
always set in the linear range of metabolite formation. Substrate concentrations were 
chosen to allow modeling of enzyme kinetics and were usually between 1 and 2000 
µM. The concentration of organic solvent was always  2% (Chauret et al., 1998). All 
incubations were performed in triplicate (n = 3). Kinetic constants were calculated via 
two ways: (a) quantification of the formed products by calibration using the 
corresponding reference standards (CRS, different concentrations between 0.001 
and 1 µM, non-linear regression, either no weighting or weighted (1/x2, where x is the 
CRS concentration), depending on investigated substrate and enzyme), (b) the peak 
areas of the products divided by those of the internal standard amitriptyline N-oxide 
(used for clozapine kinetics) or clozapine N-oxide (used for kinetics of all other 
analytes), respectively. These PARs were used instead of concentrations for 
calculating the enzyme kinetic constants. 
Enzyme kinetic constants were estimated by nonlinear curve fitting using GraphPad 
Prism 5.00 software (GraphPad Software, San Diego, USA). The Michaelis-Menten 
equation (Eq. (1)) was used to calculate apparent Km and Vmax values for single-
enzyme systems and pHLM.  
(1)                                                 
    
 
 
2.5. Calculation of relative activity factors, contributions, and percentages of net 
clearance 
The RAF approach (Crespi and Miller, 1999; Stormer et al., 2000) was based on the 
hypothesis that the human liver microsomal rates of a biotransformation mediated by 
multiple CYP isoforms could be mathematically reconstructed from the rates of the 
biotransformation catalyzed by individual recombinant CYPs (Venkatakrishnan et al., 
2001). It was used for the in vitro-in vivo scaling of pharmacokinetic clearance from in 
vitro intrinsic clearance measurements in heterologous expression systems 
(Venkatakrishnan et al., 2001). 
The turnover rates (TR) of FMO3 (probe substrate (PS) methyl p-tolyl sulfide), 
CYP1A2 (PS phenacetin), CYP2B6 (PS 7-ethoxy-4-trifluromethylcoumarin), CYP2C8 
(PS paclitaxel), CYP2C19 (PS S-mephenytoin), CYP2D6 (PS bufuralol), CYP2E1 
(PS chlorzoxazone), and CYP3A4 (PS testosterone) in insect cell microsomes (ICM) 
and pHLM were taken from the supplier's data sheets. The RAFs were calculated 
according to Eq. (2). 
 
(2)                                             
       
 
 
The enzyme velocities Venzyme (see Eq. (1)) for the respective metabolic reactions 
were calculated at different substrate concentrations and multiplied by the 
corresponding RAF leading to a value, which was defined as 'contribution' (Eq. (3)). 
The Km and Vmax values (Eq. (1)) were obtained from the incubations with cDNA-
expressed enzymes. 
 
(3)                                          
Based on these corrected activities (contributions) the percentages of net clearance 
by a particular enzyme at a certain substrate concentration can be calculated using 
Eq. (4). 
 
(4)                               
 
      
 
2.6. Apparatus and LC-conditions   
All samples were analyzed using a ThermoFisher Scientific (TF, Dreieich, Germany) 
LXQ linear IT-MS, coupled to a TF Accela ultra high performance LC (UHPLC) 
system consisting of a degasser, a quaternary pump, and an autosampler. Gradient 
el i  a  e f ed  a TF H e il GOLD C18 c l  (100 2.1 , 1.9 ). 
The mobile phase consisted of 10 mM aqueous ammonium formate plus 0.1% formic 
acid (pH 3.4, eluent A) and acetonitrile plus 0.1% formic acid (eluent B). The flow rate 
was set to 0.6 mL/min and the following gradient was used: 0-7.5 min to 5% A, 7.5-
10.0 min hold 5% A, 10.0-11.5 min to 98% A, 11.5-15.0 min hold 98% A. For 
separation of amitriptyline and its N-oxide, the flow rate was set to 0.5 mL/min and 
the gradient was programmed as follows: 0 1.0 min 98% A, 1.0 3.0 min to 90% A, 
3.0 5.0 min to 85% A, 5.0 7.5 min to 80% A, 7.5 10.0 min to 75% A, 10.0 11.5 min 
to 70% A, 11.5 13.0 min to 65% A, 13.0 14.5 min to 50% A, 14.5 16.0 min to 40% 
A, 16.0  19.0 min to 10% A, 19.0 21.0 hold 10% A, as previously described in 
(Wissenbach et al., 2011b). Analysis was performed in full-scan mode (m/z 100-800) 
or in a targeted acquisition mode with inclusion list, where MS2 spectra of given 
ec  i  e e ec ded. The i jec i  l e f  all a le  a  10 L each. 
The MS was equipped with a heated electrospray ionization II source, other 
conditions were as follows: positive ionization mode; sheath gas, nitrogen at flow rate 
of 34 arbitrary units (AU); auxiliary gas, nitrogen at flow rate of 11 AU; vaporizer 
temperature, 250°C; source voltage, 3.00 kV; ion transfer capillary temperature, 
300°C; capillary voltage, 31 V; tube lens voltage, 110 V; automatic gain control was 
set to 15,000 ions for full scan and 5,000 ions for MSn, as already described in 
(Wissenbach et al., 2011a). Wissenbach et al. described 0.01, 0.1, or 1.0 mg/L as 
limits of detection determined for several DOAs (Wissenbach et al., 2011a). 
 
2.7. Data analysis 
TF Xcalibur Qual Browser software version 2.2 SP1.48 was used for calculation of 
the peak areas for assessment of the relative amount of metabolites formed during 
incubation and GraphPad Prism 5.00 for statistical evaluations. T-test conditions 




3.1. Identification of FMO substrates by heat inactivation or chemical inhibition 
Incubations of 12 therapeutic drugs using untreated pHLM or preheated pHLM (55°C, 
1 min) were conducted. The unchanged drugs, N-oxides, and nor metabolites were 
analyzed by LC-IT-MS. Ten out of 12 substrates formed the corresponding N-oxides 
and nor metabolites in incubations with untreated pHLM. For venlafaxine, only the 
nor metabolite and for ranitidine, no metabolites could be detected. Untreated pHLM 
incubations were used as control and the amount of metabolite formed, minus 
metabolite formation in blank samples, was defined as 100%. In comparison to 
metabolite formation in untreated pHLM incubations, heat-treated (55°C) pHLM 
incubations showed a reduced formation for both metabolites each between 60 and 
100% as shown in Fig. 2a. The lowest reduction was observed for the metabolites of 
doxepin, followed by those of amitriptyline, citalopram, prothipendyl, zolpidem, and 
zopiclone. For clozapine, diphenhydramine, doxylamine, and imipramine, N-
oxygenation could not be observed. 
Results of incubations with amitriptyline, clozapine, imipramine, and zopiclone with 
pHLM, preheated at 45°C for 5 min, are shown in Fig. 2b. Here again a reduction of 
the formation rates of both metabolites was observed, although less pronounced then 
after preincubation of pHLM at 55°C. The reduction was between 30 and 50%, 
except for imipramine N-oxide formation that was reduced by 80%. Additionally, 
these four therapeutic drugs were incubated with recombinant FMO3 under 
conditions as described in 2.3. In these incubations, nor metabolites were not formed 
at all.  
Furthermore, amitriptyline, clozapine, imipramine, and zopiclone were incubated 
using pHLM preincubated with ABT or methimazole. Results are shown in Fig. 3. 
After preincubation with ABT (Fig. 3a), formation of the N-oxides of amitriptyline and 
clozapine was reduced by about 80%, while the N-oxygenation of imipramine 
remained unchanged and that of zopiclone was almost entirely prevented. In each 
case, an almost complete disappearance of the nor metabolites could be observed. 
After preincubation with methimazole (Fig. 3b), formation rates of both metabolites 
were affected and reduced between 70 and 90%. Incubations with recombinant 
FMO3, preincubated with ABT and regenerating system for 30 min were performed, 
under conditions as already described in 2.2. and 2.3. There was no difference in the 
N-oxide formation between incubations with and without ABT preincubation.  
 
3.2. Identification of enzymes involved in the N-oxygenation 
A monooxygenases activity screening using FMO3, ten CYP isoforms, or pHLM was 
conducted. The unchanged drugs, N-oxygenation products, and main metabolites 
(usually nor and mono hydroxy metabolites) were analyzed by LC-IT-MS. The 
corresponding N-oxygenation product was detected in all incubations with pHLM, 
except for methamphetamine. While the highest amount of zopiclone N-oxide was 
detected in incubations with CYP3A4, FMO3 showed no activity. Low amounts of 
imipramine N-oxide were found in incubations with FMO3 and also CYP1A2, 
CYP2B6, CYP2C19, and CYP2D6. N-Oxide formation of amitriptyline and clozapine 
was observed for FMO3 and various CYP isoforms. 
N-Oxygenation of the DOAs 3-bromomethcathinone (3-BMC), N,N-diallyltryptamine 
(DALT), DMT, methoxypiperamide (MeOP), and methamphetamine was catalyzed by 
FMO3 and some CYPs, while N-oxygenation of dextromethorphan, glaucine, and 
methadone was not catalyzed by FMO3 but by CYPs. 
 
3.3. Kinetic studies, calculation of contributions, and hepatic clearances using a 
modified RAF approach  
The kinetics for all N-oxygenations is depicted in Fig. 4 and followed classic 
Michaelis-Menten kinetics. The corresponding Michaelis-Menten constants are 
summarized in Table 1. If product inhibition was observed, high concentrations were 
excluded for calculations of Km and Vmax values. In general, CYPs showed higher 
affinity, represented by lower Km values, in comparison to higher Km values for 
FMO3. As pHLM contained all tested individual enzymes, resulting Km values were 
between CYP and FMO3 values. FMO3 showed the highest turnover rates (Vmax), 
followed by pHLM and CYPs. Calculations using CRS and PAR resulted in similar Km 
values, while Vmax values obtained by different methods could not be compared due 
to different units (pmol/min/mg for CRS and AU/min/mg for PAR). The RAFs for used 
recombinant enzymes were calculated according to Eq. (2). Turnover rates for 
appropriate probe substrates were taken from the supplier's data sheets. Applying 
the RAF approach, the contribution and in vivo hepatic net clearance was calculated 
with Km and Vmax values determined by CRS or PAR. The results for the hepatic net 
clearance of amitriptyline N-oxide at different amitriptyline concentrations are given in 
Fig. 5. The results for the hepatic net clearance of the N-oxygenation products of 
clozapine and five DOAs at a substrate concentration of 0.1 µM are given in Fig. 6. 
Results for all tested therapeutic drugs and DOAs at different substrate 
concentrations are given in Table 2. Concerning amitriptyline and clozapine, FMO3 
played only a minor role in the hepatic N-oxide clearance, while various CYPs were 
responsible for the major part of the N-oxide formation. In case of amitriptyline N-
oxide formation, contribution showed almost equal distribution among CYP1A2, 
CYP2B6, and CYP2D6, while CYP3A4 was predominantly responsible for clozapine 
N-oxide formation. N-Oxygenation of 3-BMC showed a similar profile as amitriptyline, 
concerning a distribution among various CYPs and a low contribution of FMO3. For 
DALT and methamphetamine, only FMO3 and a single CYP isoform (CYP3A4 or 
CYP2D6, respectively) were involved in the N-oxygenation, whereby FMO3 played 
the predominant role with contributions > 80% to the hepatic clearances. For DMT 
and MeOP N-oxygenation, contribution was distributed more equally between FMO3 
(50 and about 30%, respectively) and two CYP isoforms.  
The results of incubations of the five DOAs using pHLM pretreated with the CYP 
inhibitor ABT are summarized in Fig. 7. Formation of the nor metabolites was 
significantly reduced by 80% for DALT or DMT and by 90% for MeOP or 
methamphetamine in comparison to the formation in control incubations. There was 
no nor 3-BMC detectable after preincubation with ABT. Residual formation of 3-BMC 
hydroxylamine was also reduced by 90%, of methamphetamine hydroxylamine by 
50%, of MeOP N-oxide by 30%, and of DALT N-oxide and DMT N-oxide by 10% in 




4.1. Identification of FMO substrates by heat inactivation or chemical inhibition 
FMOs and CYPs are both known to catalyze N-oxygenation (Cashman and Zhang, 
2006), while CYPs, but not FMOs, catalyze nor metabolite formation via N-
dealkylation, too. Thermal inactivation was supposed to be a suitable approach for 
elucidating the FMO activity. In the absence of NADPH, FMO3 was thermally labile 
and about 60 - 80% of enzyme activity was lost after heat treatment (50 - 60°C) for 
as short as 1 min (Cashman, 2008). No details about the mechanism behind this 
observation were given by the authors. Amitriptyline, clozapine, diphenhydramine, 
imipramine, prothipendyl, and ranitidine were already described as substrates of 
FMO isoforms of different species (Krueger and Williams, 2005). In the present 
study, out of 12 tested substrates, known for N-oxygenation and N-dealkylation of 
their tertiary amine group, 11 showed formation of nor metabolites and 10 of N-
oxides after incubations with untreated pHLM. Only ranitidine was neither N-
oxygenated nor N-demethylated under the chosen incubation conditions. 
Furthermore, data obtained by heat-treated pHLM incubations could not be used to 
determine the role of FMOs in the formation of N-oxides, because the nor metabolite 
formation was also reduced even though CYPs should catalyze this reaction. A 
possible explanation would be the sensitivity of both, FMOs and CYPs to the used 
heat treatment, although FMO should be more sensitive to thermal inactivation under 
similar conditions (Cashman, 2008). To verify these results, a second heat 
inactivation protocol was tested for selected drugs using milder conditions (45°C, 5 
min) according to Taniguchi-Takizawa et al. (Taniguchi-Takizawa et al., 2015). For 
further experiments, amitriptyline, clozapine, and imipramine were chosen as known 
substrates of FMO and zopiclone showing highest N-oxide formation rate in the 
pHLM incubations. Again, both metabolic reactions were reduced by a comparable 
extend and significantly in comparison to untreated pHLM concerning amitriptyline, 
clozapine, and zopiclone. The formation of the imipramine N-oxide was reduced to a 
greater extent than that of the nor metabolite. Incubations with recombinant FMO3 
confirmed the assumption that FMO3 was not involved in the nor metabolite 
formation, which supported the conclusion that CYPs were also thermally unstable.  
As heat inactivation did not allow assessing the FMO contribution to N-oxide 
formations, chemical inhibitors were used to get further information. The first strategy 
was the inactivation of microsomal CYPs using preincubations with ABT, a known 
mechanism-based, non-specific CYP inhibitor. Although non-specific, ABT showed 
different inhibitor potencies towards the CYP isoforms (Emoto et al., 2003). The 
following CYP isoform-specific reactions were used to test for sufficient ABT 
inhibition: 4-hydroxylation of bupropion for CYP2B6, N-deethylation of amodiaquine 
for CYP2C8, 5-hydroxylation of omeprazole for CYP2C19, and O-demethylation of 
dextromethorphan for CYP2D6 (U.S.Department of Health and Human Services et 
al., 2006). Incubations were conducted as described by Dinger et al. (Dinger et al., 
2014). The formation of 4-hydroxy bupropion, N-deethyl amodiaquine, 5-hydroxy 
omeprazole, and O-demethyl dextromethorphan in pHLM preincubated with ABT was 
compared with the formation in incubations with untreated pHLM. Formation of these 
metabolites was almost entirely suppressed after treatment with ABT (remained 
formation between 0 and 6%). The almost complete disappearance of the nor 
metabolites of amitriptyline, clozapine, imipramine, and zopiclone was in line with 
these findings (Fig. 3a). As ABT did not inactivate FMOs (Mathews et al., 1985), the 
remaining N-oxide formation should be catalyzed by FMOs. Results of incubations 
with recombinant FMO3 and ABT were in line with findings of Mathews et al. and 
allowed the conclusion that the zopiclone N-oxide was exclusively formed by CYPs. 
The unaffected imipramine N-oxide formation indicated the predominant role of 
FMOs in this reaction. For amitriptyline and clozapine N-oxygenation, FMOs and also 
CYPs seemed to be involved. 
On the other hand, FMO inactivation should be possible by methimazole (Hamman et 
al., 2000). However, not only the formation of the N-oxides but also of the nor 
metabolites was significantly reduced. Hence, methimazole seemed to inhibit CYPs 
as well. These findings are in line with Guo et al. (Guo et al., 1997), who already 
described methimazole as CYP inhibitor, but are in contrast to Taniguchi-Takizawa et 
al., who reported that methimazole had only little influence on the benzydamine N-
demethylation (Taniguchi-Takizawa et al., 2015). This again underlined the 
inconsistency in protocols concerning FMO3 incubation. However, as heat 
inactivation and chemical inhibition protocols were initially intended to identify FMO 
substrates and as the results obtained by both methods were not unambiguous, 
single enzyme incubations were finally chosen to identify enzymes involved in the N-
oxygenation of the selected DOAs. 
 
4.2. Identification of enzymes involved in the N-oxygenation  
The aim was to identify all involved enzymes in the N-oxygenation of four therapeutic 
drugs and eights DOAs. Therefore, the established CYP initial activity screening 
approach (Caspar et al., 2015; Meyer et al., 2013c; Meyer et al., 2014) was extended 
for FMO3. Five functional forms of FMO in humans are known with controversial data 
concerning their role in drug metabolism. In 2006, Cashman and Zhang identified 
FMO5 as most abundant FMO in the adult liver (Cashman and Zhang, 2006), 
followed by FMO3 and very little amounts of FMO1, 2, and 4. Other authors 
described FMO3 as major isoform, including the most recent work by Chen et al. 
(Cashman, 1995; Chen et al., 2016; Overby et al., 1997). However, FMO5 is 
distinctly different from the other isoforms and does not catalyze the oxygenation of 
common FMO substrates (Cashman and Zhang, 2006). Hence, FMO3 represents the 
major enzyme involved in the human hepatic FMO-catalyzed metabolism and was 
therefore selected for further in vitro studies. For identification of the 
monooxygenases catalyzing the initial metabolic steps, FMO3 and the ten major 
human hepatic CYPs (Strolin et al., 2007) were incubated under conditions allowing 
a statement on the qualitative involvement of a particular enzyme. Incubations with 
pHLM were conducted as positive control. All expected N-oxygenation products 
could be detected, except for methamphetamine, probably due to methamphetamine 
hydroxylamine levels below the detection limit. 
Again, the monooxygenases activity screening showed zopiclone to be no substrate 
of FMO3. This further underlined the assumption that heat treatment and 
preincubation with methimazole had a negative influence on the activity of CYPs. 
Findings were also in line with the ABT inhibition results, where metabolite formation 
was almost totally reduced after ABT preincubation.  
The amount of amitriptyline and imipramine N-oxide formed by FMO3 was very low. 
Both drugs were already described as substrates of FMO1 (Krueger and Williams, 
2005; Phillips and Shephard, 2008). The small formation rates were in accordance to 
findings by Lemoine et al. They reported that human kidney preparations but not 
HLM catalyzed the N-oxygenation of imipramine and assumed the existence of 
different FMO isoforms (Lemoine et al., 1990), while more recent works identified 
FMO1 as most prevalent FMO in the adult kidney (Cashman and Zhang, 2006). The 
detection of small amounts of the imipramine N-oxide in incubations with FMO3 in 
the present work might be due to more sensitive detection methods. Nevertheless, 
imipramine N-oxide formation was not negatively affected by treatment of pHLM with 
ABT in contrast to nor metabolite formation, even if the N-oxide was not exclusively 
formed by FMO3. Maybe the FMO activity increased after inhibition of CYPs. Not 
only imipramine, but also amitriptyline could be identified as FMO3 substrate. Breyer-
Pfaff and Bull et al. described amitriptyline and imipramine as substrates of non-
human FMOs (Breyer-Pfaff, 2004; Bull et al., 1999), while Venkatakrishnan et al. 
referred to amitriptyline N-oxygenation as minor pathway in humans 
(Venkatakrishnan et al., 2001). As the current results of the monooxygenases activity 
screening showed, the N-oxides of amitriptyline and clozapine were formed by FMO3 
and CYPs, which confirmed the decreased formation after pretreatment of pHLM with 
ABT. For clozapine, the obtained results were in line with previous findings (Wang et 
al., 2015).  
Furthermore, eight DOAs were investigated using the monooxygenases activity 
screening. These DOAs were chosen because of their different chemical structures 
containing amine groups (see Fig. 1) and/or their known metabolic N-oxygenation 
(Cashman et al., 1999; Meyer et al., 2013b; Meyer et al., 2015; Meyer et al., 2012; 
Michely et al., 2015; Riba et al., 2012). Methamphetamine was already identified as 
substrate of human FMO3 (Cashman et al., 1999). 3-BMC, DALT, 
dextromethorphan, DMT, glaucine, MeOP, and methadone have not been tested for 
N-oxygenation by FMO3. The N-oxide formation of dextromethorphan, glaucine, and 
methadone was not catalyzed by human FMO3 most probably due to sterical 
hindrance. Methamphetamine, 3-BMC, DALT, DMT, and MeOP were identified to be 
FMO3 substrates. However, N-oxygenation was not exclusively catalyzed by FMO3, 
but also by different CYP isoforms.  
 
4.3. Kinetic studies, calculation of contributions, and hepatic clearances using a 
modified RAF approach  
Chen et al. described the mean protein amount of FMO3 to be 46 pmol/mg in HLM 
(Chen et al., 2016), which corresponded to CYP1A2 levels (42 pmol/mg HLM protein) 
(Shimada et al., 1994). The RAF approach was described as tool to transfer 
recombinant enzyme kinetic data to human liver activity (Stormer et al., 2000). 
Activity data provided by the manufacturer were used to calculate the RAF within this 
study (Stormer et al., 2000). 
The two therapeutic drugs amitriptyline and clozapine and their corresponding N-
oxides were used to compare the hepatic net clearances calculated via CRS or PAR. 
As already described by Meyer et al., missing analytical standards for absolute 
quantification of formed metabolites might be a bottleneck in the assessment of 
kinetic data (Meyer et al., 2013a). The use of simple PAR of formed metabolite and 
internal standard was an alternative to calculate the contribution of enzymes to the 
hepatic clearance (Meyer et al., 2013a). As shown in Table 2, there was no 
significant difference in contributions calculated via CRS and PAR for amitriptyline 
and clozapine. Hence, relative Vmax values were a useful tool for comparison of 
velocities of different enzymes catalyzing the same reaction and for assessing their 
contributions to the hepatic clearance. In conclusion, neither CRS nor PAR had 
substantial impact on the estimation of in vivo hepatic net clearance. This was in line 
with previous findings (Meyer et al., 2013a). 
Results for amitriptyline and clozapine indicated that FMO3 only played a minor role 
in their hepatic clearance as only 1 - 8% of amitriptyline and clozapine were excreted 
as N-oxide (Santagostino et al., 1974; Schaber et al., 1998). However, as the 
amitriptyline N-oxide was formed immediately after administration and disappeared 
soon, the N-oxygenation wa  di c ed a  emergency  route of metabolism for high 
drug levels (Santagostino et al., 1974). This assumption was consistent with the 
findings presented here of high FMO3 Km and Vmax values, indicating a fast 
metabolism of high drug levels.  
N-Oxygenation after CYP inhibition in pHLM was about 20% and thus higher than 
expected. Possible explanations were that either FMO3 worked more efficiently if 
CYPs were inhibited or the involved CYPs were not completely inhibited by ABT. 
However, these results confirmed the low contribution of FMO3 calculated via the 
RAF approach. RAF calculations were also done for different substrate 
concentrations (0.1 - 25 µM) to cover different concentration ranges but only minor 
changes in calculated in vivo enzyme contributions were observed. 
Dextromethorphan, glaucine, and methadone were not metabolized by FMO3 and no 
further investigations were conducted, as the hepatic clearance of their N-oxides was 
expected to be only CYP-mediated. 
Concerning the five DOAs identified as FMO3 substrates, only PAR could be used 
for calculating in vivo contribution. 3-BMC hydroxylamine was predominantly formed 
by CYP isoforms, while the formation of all other N-oxides was mainly FMO3-
dependent. In order to confirm these calculations, pHLM incubations after ABT 
inhibition were performed and nor metabolites were monitored to verify successful 
CYP inhibition. 3-BMC hydroxylamine formation was significantly reduced after CYP 
inhibition but N-oxygenation of the other DOAs was not influenced by ABT inhibition 
and remained at more than 50% of formation in control incubations. These data fitted 
well with the higher contributions of FMO3 calculated using the RAF approach. 
FMO3 contribution did not change with increasing substrate concentrations 
calculated based on reported DMT and methamphetamine plasma concentrations 
(Huestis and Cone, 2007; Oliveira et al., 2012).  
As FMO3 and different CYP isoforms (one in case of DALT and methamphetamine, 
two for DMT and MeOP, up to five for 3-BMC) were involved in the hepatic clearance 
of the N-oxygenation products of all investigated DOAs, a clinically relevant 
interaction with single inhibitors should not be expected. In addition, further metabolic 
steps were described to contribute to the total hepatic clearance (Cashman et al., 
1999; Meyer et al., 2013b; Meyer et al., 2015; Meyer et al., 2012; Michely et al., 
2015; Riba et al., 2012). Finally, FMO3 was not expected to be induced or inhibited 
by other substances (Cashman and Zhang, 2006) as described for CYPs.  
 
5. Conclusions 
Only single enzyme incubations were suitable for unambiguous identification of 
FMO3 substrates as heat inactivation and chemical inhibition provided contradictory 
results. Kinetic parameters of the N-oxygenation reactions were determined using the 
involved, recombinant enzymes. Finally, FMO3 was included for the first time in the 
RAF approach and its contribution to the human, hepatic clearance could be 
calculated. FMO3 was identified as enzyme mainly responsible for the formation of 
N,N-diallyltryptamine N-oxide and methamphetamine hydroxylamine (> 80% 
contribution for both). A contribution of 50 and 30% was calculated for the formation 
of N,N-dimethyltryptamine N-oxide and methoxypiperamide N-oxide, respectively. 
However, FMO3 contributed with less than 5% to the formation of 3-
bromomethcathinone hydroxylamine, amitriptyline N-oxide, and clozapine N-oxide. 
There was no significant difference in the contributions when using calibrations with 
reference metabolite standards or peak area ratio calculations. As the application of 
the RAF approach containing FMO3 was not described in literature so far, the 
importance of FMO3 in the N-oxygenation of DOAs in human metabolism was shown 
for the first time here. 
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Table 1 Determined Michaelis-Menten values (percentage errors in brackets) for each formed metabolite by corresponding enzymes 1 
(FMO3, pHLM, CYPs), calculated using corresponding reference standards (CRS) or peak area ratios (PAR). All Km values were given 2 





Michaelis-Menten values, Km / Vmax 




1689 (20) / 
1323 (14) 
90 (13) / 
28 (4) 
125 (13) / 
149 (6) 
9.3 (37) / 
60 (13) 
ND 
6.0 (20) / 
68 (4) 






1671 (20) / 
20 (14) 
86 (13) / 
0.43 (4) 
115 (13) / 
2.3 (6) 
8.9 (36) / 
0.93 (13) 
ND 
6.4 (27) / 
1.2 (5) 






147 (13) / 
790 (4) 
11 (23) / 
49 (6) 
9.5 (17) / 
54 (5) 
ND 
7.2 (19) / 
25 (6) 
3.1 (32) / 
244 (10) 
22 (15) / 
14 (5) 
ND 





147 (13) / 
2.0 (4) 
11 (24) / 
0.13 (6) 
9.6 (18) / 
0.14 (5) 
ND 
7.0 (19) / 
0.02 (5) 
3.2 (31) / 
0.17 (12) 
21 (18) / 
0.01 (5) 
ND 





3022 (8) / 
12 (5) 
893 (11) / 
0.62 (5) 
2927 (11) / 
7.0 (7) 
165 (11) / 
1.1 (3) 
ND 
229 (10) / 
4.2 (3) 
ND 
1498 (7) / 
3.8 (4) 
552 (11) / 
1.8 (4) 
DALT N-oxide PAR 
355 (14) / 
34 (6) 
300 (18) / 
0.35 (7) 
ND ND ND ND ND ND 
131 (26) / 
0.23 (10) 
DMT N-oxide PAR 
421 (7) / 
164 (3) 
307 (10) / 
4.2 (4) 
172 (9) / 
9.7 (3) 
ND ND 
107 (9) / 
1.8 (3) 
ND ND ND 
MeOP N-oxide PAR 
671 (4) / 
15 (2) 
517 (9) / 
1.0 (4) 
ND ND ND 
55 (8) / 
2.9 (2) 
ND ND 





13483 (29) / 
15 (22) 
ND ND ND ND ND 




  5 
Table 2 Calculated in vivo hepatic net clearance [%] of the N-oxygenation products for the used enzymes (FMO3, CYPs) at different 6 





Hepatic net clearance at a substrate concentration of 0.1 / 1 / 10 / 25 µM [%] 
FMO3 CYP1A2 CYP2B6 CYP2C8 CYP2C19 CYP2D6 CYP2E1 CYP3A4 
Amitriptyline  
N-oxide 
CRS 1 / 1 / 2 / 2 
25 / 27 / 37 / 
47 
36 / 35 / 28 / 
22 
 9 / 8 / 5 / 4 
29 / 29 / 28 / 
25 
  
 PAR 1 / 1 / 2 / 2 
25 / 27 / 37 / 
48 
36 / 35 / 28 / 
22 
 9 / 8 / 5 / 4 





CRS 1 / 1 / 1 / 2 5 / 5 / 5 / 5  5 / 5 / 5 / 4 3 / 2 / 1 / 1 
<1 / <1 / <1 / 
<1 
 
86 / 87 / 88 / 
88 
 PAR 2 / 2 / 3 / 5 
16 / 16 / 16 / 
15 
 5 / 5 / 4 / 4 2 / 2 / 2 / 1 
<1 / <1 / <1 / 
<1 
 




PAR 4 / 4 / 4 / 4 
16 / 16 / 17 / 
17 
22 / 21 / 21 / 
20 
 6 / 6 / 5 / 5  
28 / 29 / 29 / 
30 
24 / 24 / 24 / 
24 
DALT N-oxide PAR 
90 / 90 / 91 / 
91 
      
10 / 10 / 9 / 
9 
DMT N-oxide PAR 
49 / 49 / 50 / 
51 
50 / 50 / 49 / 
48 
  1 / 1 / 1 / 1    
MeOP N-oxide PAR 
32 / 32 / 33 / 
34 
   
24 / 24 / 21 / 
18 
  





84 / 84 / 85 / 
85 
    
16 / 16 / 15 / 
15 
  
Legends to the Figures 8 
 9 
Fig. 1. Chemical structures of tested drugs of abuse in alphabetic order. 10 
 11 
Fig. 2. Effect of heat treatment of pHLM (a: 55°C, 1 min; b: 45°C, 5 min) on the 12 
formation of N-oxide (open bars) and nor metabolite (shaded bars) of therapeutic 13 
drugs. Data represent formation rates relative to formation in control incubations with 14 
untreated pHLM. Values are expressed as mean and were tested for significance (n 15 
= 2; ***, P < 0.001 for formation in incubations with heat-treated pHLM versus 16 
formation in control incubations).  17 
 18 
Fig. 3. Effect of preincubation with ABT (a) or methimazole (b) of pHLM on the 19 
formation of N-oxide (open bars) and nor metabolite (shaded bars) of four therapeutic 20 
drugs. Data represent formation rates relative to formation in control incubations with 21 
untreated pHLM. Values are expressed as mean and were tested for significance (n 22 
= 2; ***, P < 0.001 for formation in incubations with pHLM preincubated with ABT or 23 
methimazole versus formation in control incubations).  24 
 25 
Fig. 4. Kinetics of FMO3, pHLM, and single CYP of the corresponding N-26 
oxygenations calculated using corresponding reference standards (CRS) or peak 27 
area ratios (PAR). Data points represent means and ranges of triplicate incubations. 28 
 29 
Fig. 5. Estimated in vivo hepatic net clearance of amitriptyline N-oxide calculated 30 
using corresponding reference standards (CRS) or peak area ratios (PAR) for 31 
different substrate concentrations. 32 
 33 
Fig. 6. Estimated in vivo hepatic net clearance of the N-oxygenation products of 34 
clozapine and different drugs of abuse using PAR at a substrate concentration of 0.1 35 
µM. 36 
 37 
Fig. 7. Effect of ABT preincubation of pHLM on the formation of N-oxygenation 38 
products (open bars) and nor metabolites (shaded bars) of five drugs of abuse. Data 39 
represent formation rates relative to formation in control incubations with untreated 40 
pHLM. Data are expressed as mean and were tested for significance (n = 2; ***, P < 41 
0.001 for formation in incubations with pHLM preincubated with ABT versus formation 42 
in control incubations).  43 
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